|
|
Blood, 15 November 2003, Vol. 102, No. 10, pp. 3829-3836.
Prepublished online as a Blood First Edition Paper on July 24, 2003; DOI 10.1182/blood-2003-04-1022.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
Naoto T. Ueno,
Yee Chung Cheng,
Gabriela Rondón,
Nizar M. Tannir,
James L. Gajewski,
Daniel R. Couriel,
Chitra Hosing,
Marcos J. de Lima,
Paolo Anderlini,
Issa F. Khouri,
Daniel J. Booser,
Gabriel N. Hortobagyi,
Lance C. Pagliaro,
Eric Jonasch,
Sergio A. Giralt, and
Richard E. Champlin
From the Departments of Blood and Marrow Transplantation, Breast Cancer Research Program, Breast Medical Oncology, and Genitourinary Medical Oncology, the University of Texas M. D. Anderson Cancer Center, Houston.
We evaluated the feasibility and efficacy of a reduced-intensity conditioning (RIC) regimen of fludarabine and melphalan to achieve rapid complete donor chimerism after allogeneic stem cell transplantation (SCT) in patients with metastatic solid tumors. Between January 1999 and January 2003, 8 patients with metastatic breast cancer (BC) and 15 with metastatic renal cell carcinoma (RCC) underwent allogeneic SCT after an RIC regimen of 5 days of fludarabine and 2 days of melphalan. Filgrastim-mobilized stem cells from HLA-identical related or unrelated donors were infused. Prophylaxis for graft-versus-host disease (GVHD) consisted of tacrolimus and methotrexate. All 22 evaluable patients had 100% donor chimerism at day 30 and at all measurement times thereafter. One patient died 19 days after SCT. Nine patients (39%) had grades II to IV acute GVHD and 10 patients (43%) had chronic GVHD. Five patients (22%) died of nonrelapse treatment-related complications. Treatment-related disease response was seen in 10 patients (45%), with 3 complete responses, 2 partial responses, and 5 minor responses. Fludarabine-melphalan is a feasible and effective RIC regimen for allogeneic SCT in metastatic BC and RCC. It induces rapid complete donor chimerism without the need for donor lymphocyte infusion. Tumor regression associated with GVHD is consistent with graft-versus-tumor effect. (Blood. 2003;102:3829-3836)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Ishiyama, A. Takami, S. Suzuki, H. Konaka, M. Namiki, A. Ooi, and S. Nakao
Relationship Between Tumor-infiltrating T Lymphocytes and Clinical Response After Reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Renal Cell Carcinoma: A Single Center Prospective Study
Jpn. J. Clin. Oncol.,
December 1, 2009;
39(12):
807 - 812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kawase, K. Matsuo, K. Kashiwase, H. Inoko, H. Saji, S. Ogawa, S. Kato, T. Sasazuki, Y. Kodera, Y. Morishima, et al.
HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism
Blood,
March 19, 2009;
113(12):
2851 - 2858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Tykodi, N. Fujii, N. Vigneron, S. M. Lu, J. K. Mito, M. X. Miranda, J. Chou, L. N. Voong, J. A. Thompson, B. M. Sandmaier, et al.
C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients
Clin. Cancer Res.,
August 15, 2008;
14(16):
5260 - 5269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Eto, Y. Kamiryo, A. Takeuchi, M. Harano, K. Tatsugami, M. Harada, K. Kiyoshima, M. Hamaguchi, T. Teshima, M. Tsuneyoshi, et al.
Posttransplant Administration of Cyclophosphamide and Donor Lymphocyte Infusion Induces Potent Antitumor Immunity to Solid Tumor
Clin. Cancer Res.,
May 1, 2008;
14(9):
2833 - 2840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Conrad, M. Remberger, K. Cederlund, O. Ringden, and L. Barkholt
A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors
Haematologica,
February 1, 2008;
93(2):
265 - 272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Carella, R. Ferrara, G. F. Orcioni, G. Pepe, and G. Villavecchia
Profound graft-versus-tumor response in metastatic breast cancer with nonmyeloablative allografting
Ann. Onc.,
October 1, 2007;
18(10):
1751 - 1754.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Carella and M. Bregni
Current role of allogeneic stem cell transplantation in breast cancer
Ann. Onc.,
October 1, 2007;
18(10):
1591 - 1593.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Eto, M. Harano, K. Tatsugami, M. Harada, Y. Kamiryo, K. Kiyoshima, M. Hamaguchi, M. Tsuneyoshi, Y. Yoshikai, and S. Naito
Cyclophosphamide-Using Nonmyeloablative Allogeneic Cell Therapy against Renal Cancer with a Reduced Risk of Graft-versus-Host Disease
Clin. Cancer Res.,
February 1, 2007;
13(3):
1029 - 1035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Yang and R. Childs
Immunotherapy for Renal Cell Cancer
J. Clin. Oncol.,
December 10, 2006;
24(35):
5576 - 5583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Carnevale-Schianca, A. Cignetti, A. Capaldi, K. Vitaggio, A. Vallario, A. Ricchiardi, E. Sperti, R. Ferraris, M. Gatti, G. Grignani, et al.
Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD
Blood,
May 1, 2006;
107(9):
3795 - 3803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ohashi, A. Kobayashi, H. Hara, Y. Miura, K. Yoshida, M. Kushida, Y. Ikarashi, M. Mandai, M. Kitajima, T. Yoshida, et al.
Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
Clin. Cancer Res.,
April 1, 2006;
12(7 Pt 1):
2208 - 2215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Harano, M. Eto, T. Iwai, K. Tatsugami, K. Kiyoshima, Y. Kamiryo, M. Tsuneyoshi, Y. Yoshikai, and S. Naito
Renal Cancer Treatment with Low Levels of Mixed Chimerism Induced by Nonmyeloablative Regimen Using Cyclophosphamide in Mice
Cancer Res.,
November 1, 2005;
65(21):
10032 - 10040.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Thompson and M. Fishman
Management of Metastatic Renal Cancer
J Natl Compr Canc Netw,
January 1, 2005;
3(1):
105 - 113.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. S. Tykodi, E. H. Warren, J. A. Thompson, S. R. Riddell, R. W. Childs, B. E. Otterud, M. F. Leppert, R. Storb, and B. M. Sandmaier
Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning: Toxicity, Clinical Response, and Immunological Response to Minor Histocompatibility Antigens
Clin. Cancer Res.,
December 1, 2004;
10(23):
7799 - 7811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dorrschuck, A. Schmidt, E. Schnurer, M. Gluckmann, C. Albrecht, C. Wolfel, V. Lennerz, A. Lifke, C. Di Natale, E. Ranieri, et al.
CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression
Blood,
October 15, 2004;
104(8):
2591 - 2599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. T. Ueno, E. J. Shpall, R. E. Champlin, and R. B. Jones
Graft--Versus--Breast Cancer Effect by Allogeneic Hematopoietic Stem-Cell Transplantation: A Possible New Frontier
J. Clin. Oncol.,
October 1, 2004;
22(19):
3846 - 3847.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Takahashi and R. W. Childs
Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma
Clin. Cancer Res.,
September 15, 2004;
10(18):
6353S - 6359S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Igarashi, J. Wynberg, R. Srinivasan, B. Becknell, J. P. McCoy Jr, Y. Takahashi, D. A. Suffredini, W. M. Linehan, M. A. Caligiuri, and R. W. Childs
Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells
Blood,
July 1, 2004;
104(1):
170 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
